Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia
NCT05816343Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 hyperlipoproteinemia (FCS) comparing Orlistat Drug with Placebo (2 arms). Primary endpoint: Change in Triglycerides at 24 weeks. Started Jan 2024; status: recruiting.
02
Drugs
orlistat
03
Conditions
type 1 hyperlipoproteinemia (FCS)
Beyond the preview
Go deeper on NCT05816343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816343.